| Balance Sheet Information |
2. Balance Sheet Information
Cash, Cash Equivalents and Restricted Cash
A summary of cash and cash equivalents and restricted cash is as follows:
|
|
|
|
|
|
|
|
|
September 30, 2022 |
|
|
|
|
|
(unaudited) |
|
December 31, 2021 |
Cash and Cash Equivalents |
|
$ |
4,801,616 |
|
$ |
7,854,690 |
Restricted Cash, Non-current |
|
|
49,037 |
|
|
45,000 |
Total Cash, Cash Equivalents and Restricted Cash |
|
$ |
4,850,653 |
|
$ |
7,899,690 |
Non-current restricted cash consists of deposits with financial institutions for corporate credit cards.
Prepaid Expenses and Other Current Assets
Prepaid expenses consist of the following:
|
|
|
|
|
|
|
|
|
September 30, 2022 |
|
|
|
|
|
(unaudited) |
|
December 31, 2021 |
Prepaid Insurance |
|
$ |
97,617 |
|
$ |
130,765 |
Prepaid Research and Development |
|
|
36,760 |
|
|
319,208 |
Other |
|
|
125,628 |
|
|
156,547 |
Total Prepaid Expenses and Other Current Assets |
|
$ |
260,005 |
|
$ |
606,520 |
Accrued Expenses
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
September 30, 2022 |
|
|
|
|
|
(unaudited) |
|
December 31, 2021 |
Executive Severance |
|
$ |
666,784 |
|
$ |
200,605 |
Payroll and Benefits |
|
|
550,133 |
|
|
737,365 |
Professional Fees |
|
|
442,605 |
|
|
194,425 |
Clinical Trials |
|
|
124,858 |
|
|
168,785 |
Other |
|
|
15,630 |
|
|
28,961 |
Total Accrued Expenses |
|
$ |
1,800,010 |
|
$ |
1,330,141 |
|